Walk-in STI testing and treatment in NYC and Long Island

STI testing works best when the tests match your symptoms, exposure sites and timing. You can request routine screening, evaluation after a partner’s diagnosis or care for symptoms. A broad panel may be useful, but there is no single test that rules out every STI at every body site. A respectful visit should explain what is included, what is omitted and what the next step will be for each result.

Different tests detect different organisms or the immune response to them. Chlamydia and gonorrhea commonly use NAAT on urine or swabs. HIV and syphilis generally use blood testing. A symptomatic sore may need a lesion swab; cervical HPV screening serves a different purpose from a general STI panel. Results cannot be interpreted simply as ‘clean’ or ‘not clean.’ An infection is a health issue, not a judgment about a person.

Screening recommendations reflect age, anatomy, pregnancy, sexual practices and previous infections. You do not need symptoms to have an infection. If you have burning, discharge, sores, a rash or pelvic pain, request evaluation as well as tests. Tell the clinician about pregnancy, PrEP/PEP, previous positive results and recent antibiotics. A recent qualifying HIV exposure within 72 hours needs urgent PEP assessment.

Review the reason for testing. A specific partner diagnosis may need a focused test plus related screening. A panel should have a written list of infections and specimens, not just a reassuring name.

Discuss oral, anal and vaginal contact so throat, rectal or genital samples can be included when appropriate. A urine-only panel cannot rule out infection at unsampled sites.

Ask how results are delivered and which clinician acts on a positive, reactive or invalid result. Some screenings require confirmation. Treatment may be started on clinical grounds in selected situations, but a collection visit alone is not a prescription.

Discuss partner evaluation, repeat screening, vaccination and HIV prevention. After treatment, test of cure and reinfection screening are different tasks with infection-specific timing.

Review every result, including pending or indeterminate tests, rather than assuming silence means everything is negative. A positive infection needs its treatment and partner plan. Ongoing screening frequency reflects risk and any PrEP/doxy-PEP program. If symptoms persist despite negative tests, return for an examination and consideration of other causes.

STI and STD refer to the same infection/testing concern. Testing depends on symptoms, exposure date, sexual contact sites, pregnancy and prior results; there is no universal panel that excludes every STI. Blood is used for infections such as HIV and syphilis, while chlamydia/gonorrhea testing may need urine or genital, throat and rectal samples. A urine test does not exclude infection at an untested throat or rectal site. Ask which exact tests and specimens are included and whether a specific test is appropriate.

A clinician may treat before results return when symptoms, a known infected partner or another clinical situation warrants it. Testing should still address the exposed sites and related infections. This is an individual decision, not an automatic antibiotic prescription after every collection. Severe pelvic/testicular pain, fever, eye symptoms or a qualifying recent HIV exposure needs prompt assessment rather than waiting for routine results.

Review the reason for testing. A specific partner diagnosis may need a focused test plus related screening. A panel should have a written list of infections and specimens, not just a reassuring name.

Discuss oral, anal and vaginal contact so throat, rectal or genital samples can be included when appropriate. A urine-only panel cannot rule out infection at unsampled sites.

Ask how results are delivered and which clinician acts on a positive, reactive or invalid result. Some screenings require confirmation. Treatment may be started on clinical grounds in selected situations, but a collection visit alone is not a prescription.

Discuss partner evaluation, repeat screening, vaccination and HIV prevention. After treatment, test of cure and reinfection screening are different tasks with infection-specific timing.

Review every result, including pending or indeterminate tests, rather than assuming silence means everything is negative. A positive infection needs its treatment and partner plan. Ongoing screening frequency reflects risk and any PrEP/doxy-PEP program. If symptoms persist despite negative tests, return for an examination and consideration of other causes.

Expedited partner therapy can sometimes provide treatment for partners without their own examination for selected infections when clinically appropriate and permitted by the relevant law. It is not a universal option for every STI, pregnancy concern, allergy or exposure. The treating clinician should give specific medication, warning and evaluation instructions; partners with symptoms or HIV/syphilis concerns need their own assessment. Do not share your own leftover medicine.

Possible HIV exposure is time-sensitive. Seek PEP assessment as soon as possible, ideally within 24 hours and no later than 72 hours after a qualifying exposure. PEP is a 28-day course of antiretroviral medication used after exposure; it is different from ongoing PrEP. Do not wait for symptoms, a partner’s results, insurance approval or a routine appointment. If a clinic cannot assess you promptly, go to an emergency department or another service able to start PEP.

Tell the service the exact date and time, what happened, any prior PrEP doses and what is known about the source. If sexual assault occurred, urgent care can also address injuries, pregnancy prevention, other infections and support; PEP decisions should not wait for reporting or paperwork.

A baseline HIV test and renal, hepatic, hepatitis, STI or pregnancy testing may be needed. When PEP is indicated, the first dose should not be delayed waiting for laboratory results that are unavailable immediately.

Confirm where the medication will be dispensed, how the full 28-day supply will be obtained and whom to call for side effects or a missed dose. The regimen is selected for age, pregnancy, organ function and interactions.

CDC recommends early contact around 24 hours to check access and tolerance, with clinical/laboratory follow-up at 4–6 and 12 weeks after exposure. Your clinician specifies the HIV antigen/antibody and nucleic-acid tests and any timing adjustments.

Testing immediately after the final pill does not replace the scheduled follow-up. Antiretrovirals can affect HIV detection, so routine untreated-infection window estimates do not determine the PEP testing plan. Report fever, rash or other possible acute HIV symptoms between visits. If future exposure is likely, discuss a clinician-managed PEP-to-PrEP transition rather than leaving a prevention gap while waiting for the final test.

Contact the selected clinic with the exact testing concern, exposure date and requested specimens. Ask whether an appointment is required and what samples the service can collect; booking ahead can clarify lab capability and privacy needs. A broad panel name or walk-in policy does not establish that every test is included.

Not necessarily. Ask for the exact test list. Routine herpes blood testing has limitations, and cervical HPV screening is a separate indication-specific service. A named panel does not mean every infection or site is covered.

No. A site may see you and collect samples the same day while laboratory results return later. Confirm which tests are rapid, what confirmation may be needed and who will call you.

It may exclude the infections tested at the sampled sites within the relevant windows, but it does not diagnose every cause. Persistent symptoms need reassessment rather than repeated reassurance from the panel name.